Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.
CMS innovation center to expand team focused on drug prices
To help with new pilot models aimed at lowering drug costs across Medicaid and Medicare, CMS’ innovation center is ramping up staff. “We are on


